Editorial Disclosure: GLP-1 Editorial is an editorial publication operated by Ranika Editorial Group LLC. We do not provide medical care, prescribe medication, manufacture or compound medication, or sell GLP-1 treatment. Our rankings are based on our published v3.0 transparency rubric, publicly available provider information, cited sources, and periodic review updates. If a provider relationship, sponsorship, affiliate relationship, or material connection exists, it is disclosed on the relevant page and at /affiliate-disclosure.html.
Last reviewed: May 31, 2026
Next scheduled review: June 30, 2026
Reviewed by: Dr. Sam Saberian, Lead Medical Researcher
Edited by: Julliana Edwards, Editor
Methodology: GLP-1 Editorial v3.0 rubric
Home · Guides · 503A vs 503B Compounding Pharmacies Explained
Guide · Updated 2026-05-08

503A vs 503B Compounding Pharmacies Explained

Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.

EducationalUpdated 2026-05-08
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Overview

Plain-language guide to the difference between 503A patient-specific compounding pharmacies and 503B FDA-registered outsourcing facilities.

Related guides

Important medical and regulatory disclosure: Compounded semaglutide and compounded tirzepatide are not FDA-approved. They are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. Compounded medications may be prescribed only when clinically appropriate after review by a licensed medical provider. GLP-1 Editorial does not provide medical advice, prescribe medication, manufacture medication, or operate a pharmacy.